Delivery Order SPE2DB24D2011-SPE2DB25FBRKC
- Not listed
- The Defense Logistics Agency awarded a $41,453.26 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens, with a contract ceiling value of $52,595.52 and an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $64,225.28 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 25, 2025, with completion targeted for July 28, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $60,934.22 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Dupixent 300 mg/2 ml pens. This contract has an ultimate completion date of April 3, 2024. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) awarded by DLA with a potential value of $999,999,999.00 through December 31, 2025. This IDC serves as the primary...
- The Defense Logistics Agency awarded a delivery order valued at $8,570.57 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement executed through AmerisourceBergen's broader contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order valued at $17,771.27 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml pens. This award is part of a larger indefinite delivery contract (IDC) with DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 for the provision of a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. AmerisourceBergen, a major pharmaceutical...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,862.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $15,942.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The delivery location is AmerisourceBergen's corporate office in Conshohocken,...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRKCDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $44,236.34 on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This firm fixed-price delivery order, with an ultimate completion date of July 28, 2025, represents a competitive award with no set-aside designation. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen Drug Corp fulfills pharmaceutical procurement requirements across military and veteran healthcare systems. The SPE2DX IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and medical devices. The company's extensive contract portfolio with DLA demonstrates its capability to meet federal procurement requirements through open competition across multiple therapeutic domains and delivery scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $44.2k | 7/25/25 |